| 000 | 01628 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513034857.0 | ||
| 264 | 0 | _c19950918 | |
| 008 | 199509s 0 0 eng d | ||
| 022 | _a0306-5251 | ||
| 024 | 7 |
_a10.1111/j.1365-2125.1995.tb04465.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRolan, P E | |
| 245 | 0 | 0 |
_aPharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers. _h[electronic resource] |
| 260 |
_bBritish journal of clinical pharmacology _cApr 1995 |
||
| 300 |
_a375-80 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBenzaldehydes _xadverse effects |
| 650 | 0 | 4 |
_aBenzoates _xadverse effects |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aErythrocytes _xdrug effects |
| 650 | 0 | 4 |
_aExercise _xphysiology |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 |
_aHeart Rate _xdrug effects |
| 650 | 0 | 4 |
_aHemoglobins _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aOxygen _xmetabolism |
| 650 | 0 | 4 |
_aOxygen Consumption _xdrug effects |
| 650 | 0 | 4 |
_aPsychomotor Performance _xdrug effects |
| 650 | 0 | 4 |
_aTransaminases _xblood |
| 650 | 0 | 4 | _aWhite People |
| 700 | 1 | _aMercer, A J | |
| 700 | 1 | _aWootton, R | |
| 700 | 1 | _aPosner, J | |
| 773 | 0 |
_tBritish journal of clinical pharmacology _gvol. 39 _gno. 4 _gp. 375-80 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2125.1995.tb04465.x _zAvailable from publisher's website |
| 999 |
_c7639574 _d7639574 |
||